All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
María-Victoria MateosThe US Food and Drug Administration (FDA) has approved a once-weekly dosing regimen of carfilzomib (Kyprolis®) in combination with dexamethasone, to treat patients with relapsed and refractory multiple myeloma (MM). The new indication enables a single 70 mg/m2 dose to be administered once-weekly (along with dexamethasone), instead of the previous twice-weekly dose of 27 mg/m2.
The approval was based on the ARROW study presented at ASCO in June 2018, and previously detailed in an interview for the MM Hub by Maria Victoria Mateos. The study showed an improved PFS in patients receiving the once-weekly regimen and in addition, offers a more convenient regimen.
References
Your opinion matters
Which of the following factors is most important to you when selecting a treatment for patients with multiple myeloma?